Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery

European Journal of Pharmaceutical Sciences

Volumn 52, Issue 1, 2014, Pages 191-205

  Li, Xiaojian ^a   Vogt, Frederick G ^b   Hayes Jr , Don ^c,d   Mansour, Heidi M ^e  

^a University of Kentucky   (United States)

^b GLAXOSMITHKLINE   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aerosol dispersion performance modeling; Cystic fibrosis; Dry powder inhalers (DPIs); Glass transition; Pulmonary infections; Respiratory delivery

Indexed keywords

AZITHROMYCIN; TOBRAMYCIN;

AEROSOL; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DIFFRACTION; DISPERSION; DRUG DELIVERY SYSTEM; DRY POWDER; GLASS TRANSITION TEMPERATURE; IMAGE ANALYSIS; INFRARED SPECTROSCOPY; LASER DIFFRACTION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; THERMOGRAPHY; TITRIMETRY; WATER CONTENT; WATER VAPOR; WETTABILITY; X RAY POWDER DIFFRACTION;

AEROSOL DISPERSION PERFORMANCE MODELING; CYSTIC FIBROSIS; DRY POWDER INHALERS (DPIS); GLASS TRANSITION; PULMONARY INFECTIONS; RESPIRATORY DELIVERY;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DRUG COMPOUNDING; DRY POWDER INHALERS; METHANOL; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; POWDER DIFFRACTION; POWDERS; SOLUTIONS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL; TOBRAMYCIN; X-RAY DIFFRACTION;

EID: 84890522240     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.10.016     Document Type: Article

References (41)

1. H. Adi, D. Traini, H.K. Chan, and P.M. Young The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations J. Pharm. Sci. 97 2008 2780 2788
2. S. Adi, H. Adi, P. Tang, D. Traini, H.K. Chan, and P.M. Young Micro-particle corrugation, adhesion and inhalation aerosol efficiency Eur. J. Pharm. Sci. 35 2008 12 18
3. Burnett, D., Malde, N., Daryl, W., 2009. Characterizing Amorphous Materials with Gravimetric Vapour Sorption Techniques. Pharmaceutical Technology Europe.
4. A.K. Dash, and R. Suryanayanan Solid-state properties of tobramycin Pharm. Res. 8 1991 1159 1165
5. Finlay, W.H., 2008. The ARLA Respiratory Deposition Calculator.
6. R. Gandhi, O. Pillai, R. Thilagavathi, B. Gopalakrishnan, C.L. Kaul, and R. Panchagnula Characterization of azithromycin hydrates Eur. J. Pharm. Sci. 16 2002 175 184 (Pubitemid 34786452)
7. L. Garcia-Contreras, and A.J. Hickey Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy Adv. Drug Deliv. Rev. 54 2002 1491 1504 (Pubitemid 35375772)
8. B.C. Hancock, and G. Zografi The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids Pharm. Res. 11 1994 471 477 (Pubitemid 24144434)
9. D.J. Hayes, B.S. Murphy, T.W. Mullett, and D.J. Feola Aerosolized vancomycin for the treatment of MRSA after lung transplantation Respirology 15 2009 182 186
10. A.J. Hickey, and H.M. Mansour Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols M.J. Rathbone, Modified-Release Drug Delivery Technology 2008 Informa Healthcare New York 573 602
11. A.J. Hickey, and H.M. Mansour Delivery of drugs by the pulmonary route A.T. Florence, J. Siepmann, Modern Pharmaceutics 2009 Taylor & Francis New York 191 219
12. A.J. Hickey, H.M. Mansour, M.J. Telko, Z. Xu, H.D. Smyth, T. Mulder, R. McLean, J. Langridge, and D. Papadopoulos Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics J. Pharm. Sci. 96 2007 1282 1301 (Pubitemid 46804582)
13. A.J. Hickey, H.M. Mansour, M.J. Telko, Z. Xu, H.D. Smyth, T. Mulder, R. McLean, J. Langridge, and D. Papadopoulos Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics J. Pharm. Sci. 96 2007 1302 1319 (Pubitemid 46804583)
14. X. Li, and H.M. Mansour Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery AAPS PharmSciTech 12 2011 1420 1430
15. J.W. Lightbown, and H. Dixon The first international reference preparation of tobramycin J. Biol. Stand. 10 1982 157 168 (Pubitemid 12008482)
16. M.D. Louey, M. Van Oort, and A.J. Hickey Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques Pharm. Res. 21 2004 1200 1206 (Pubitemid 38954204)
17. Mansour, H.M., Hickey, A.J., 2007. Raman Characterization and Chemical Imaging of Biocolloidal Self-Assemblies, Drug Delivery Systems, and Pulmonary Inhalation Aerosols. A Review. AAPS PharmSciTech 8, Article 99 (E01-E16).
18. H.M. Mansour, and G. Zografi The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions J. Pharm. Sci. 96 2007 377 396 (Pubitemid 46363568)
19. H.M. Mansour, Y.S. Rhee, and X. Wu Nanomedicine in pulmonary delivery Int. J. Nanomed. 4 2009 299 319
20. S.A. Meenach, F.G. Vogt, K.W. Anderson, J.Z. Hilt, R.C. McGarry, and H.M. Mansour Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable DPPC and DPPC:DPPE-PEG microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols Int. J. Nanomed. 8 2013 275 293
21. T. Mizoe, T. Ozeki, and H. Okada Preparation of drug nanoparticle- containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms J. Controlled Release 122 2007 10 15 (Pubitemid 47284548)
22. J.F. Murray, and J.A. Nadel Textbook of Respiratory Medicine 1988 Saunders Philadelphia
23. C.W. Park, D.J. Hayes, and H.M. Mansour Pulmonary inhalation aerosols for targeted antibiotics delivery Eur. Pharmaceut. Rev. 16 2011 32 36
24. C.W. Park, Y.S. Rhee, F. Vogt, D.J. Hayes, J.B. Zwischenberger, P.P. DeLuca, and H.M. Mansour Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex-vivo in respiratory drug delivery. Invited paper Adv. Drug Deliv. Rev. 64 2012 344 356
25. D.L. Paterson Clinical experience with recently approved antibiotics Curr. Opin. Pharmacol. 6 2006 486 490 (Pubitemid 44348532)
26. W.A. Prescott Jr., and C.E. Johnson Antiinflammatory therapies for cystic fibrosis: past, present, and future Pharmacotherapy 25 2005 555 573 (Pubitemid 40471498)
27. O.G. Raabe Comparison of the criteria for sampling 'inhalable' and 'respirable' aerosols Ann. Occup. Hyg. 26 1982 33 45 (Pubitemid 13232219)
28. D. Shitrit, D. Bendayan, S. Gidon, M. Saute, I. Bakal, and M.R. Kramer Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients J. Heart Lung Transplant. 24 2005 1440 1443 (Pubitemid 41247833)
29. J.-H. Song What's new on the antimicrobial horizon? Int. J. Antimicrob. Agents 32 2008 S207 S213
30. W. Stahlhofen, J. Gebhart, and J. Heyder Experimental determination of the regional deposition of aerosol particles in the human respiratory tract Am. Ind. Hyg. Assoc. J. 41 1980 385 398a
31. S. Suarez, and A.J. Hickey Drug properties affecting aerosol behavior Respir. Care 45 2000 652 666 (Pubitemid 30484805)
32. R.F. Taylor, D.W. Morgan, P.S. Nicholson, I.S. Mackay, M.E. Hodson, and T.L. Pitt Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis Thorax 47 1992 426 428
33. The United States Pharmacopeial Convention Inc., 2006. <601> Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers Monograph, USP 29-NF 24 the United States Pharmacopoeia and The National Formulary: The Official Compendia of Standards. The United States Pharmacopeial Convention Inc., Rockville, MD, pp. 2617-2636.
34. H.A. Tiddens Detecting early structural lung damage in cystic fibrosis Pediatr. Pulmonol. 34 2002 228 231 (Pubitemid 34971078)
35. O.S. Usmani, M.F. Biddiscombe, and P.J. Barnes Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size Am. J. Respir. Crit. Care Med. 172 2005 1497 1504 (Pubitemid 43076536)
36. D. Worlitzsch, R. Tarran, M. Ulrich, U. Schwab, A. Cekici, K.C. Meyer, P. Birrer, G. Bellon, J. Berger, T. Weiss, K. Botzenhart, J.R. Yankaskas, S. Randell, R.C. Boucher, and G. Doring Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients J. Clin. Invest. 109 2002 317 325 (Pubitemid 34141805)
37. X. Wu, X. Li, and H.M. Mansour Surface analytical techniques in solid-state particle characterization: implications for predicting performance in dry powder inhalers KONA Powder Part. J. 2010 3 19
38. X. Wu, D.J. Hayes, J.B. Zwischenberger, R.J. Kuhn, and H.M. Mansour Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation Drug Des. Dev. Ther. 7 2013 59 72
39. X. Wu, W. Zhang, D.J. Hayes, and H.M. Mansour Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine a multifunctional particles for dry powder inhalation aerosol delivery Int. J. Nanomed. 8 2013 1 15
40. Z. Xu, H.M. Mansour, T. Mulder, R. McLean, J. Langridge, and A.J. Hickey Heterogeneous particle deaggregation and its implication for therapeutic aerosol performance J. Pharm. Sci. 99 2010 3442 3461
41. Z. Xu, H.M. Mansour, and A.J. Hickey Particle interactions in dry powder inhaler unit processes J. Adhes. Sci. Technol.: Spec. Iss. Adhes. Asp. Pharmaceut. Sci. 25 2011 451 482